quinazolines has been researched along with Anemia in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (50.00) | 29.6817 |
| 2010's | 10 (45.45) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Anaclerico, B; Andriani, A; Baldacci, E; Breccia, M; Cedrone, M; Cimino, G; Di Veroli, A; Latagliata, R; Mazzucconi, MG; Montanaro, M; Montefusco, E; Paoloni, F; Porrini, R; Rago, A; Santoro, C; Scaramucci, L; Spadea, A; Spirito, F; Villivà, N | 1 |
| Baselga, J; Blackwell, K; Diéras, V; Gianni, L; Green, M; Hoersch, S; Krop, IE; Miles, D; Pegram, M; Verma, S; Welslau, M; Xu, J | 1 |
| Al Mamun Bhuyan, A; Lang, F | 1 |
| Aki, A; Baba, D; Fukuda, T; Hashimoto, M; Ishiyama, T; Katagiri, T; Muramatsu, S; Tanaka, N; Ueda, K; Watanabe, K | 1 |
| Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W | 1 |
| Alvarez, C; Ferrari, L; Glembotsky, AC; Goette, NP; Gutierrez, MI; Heller, PG; Korin, L; Lev, PR; Maldonado, AC; Marta, RF; Mela Osorio, MJ; Molinas, FC | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
| Chen, MM; Conlan, MG; Escandon, RD; Gomez, HL; Kiyan, M; Monsalvo, ML; Philco, M; Pimentel, P; Saikali, KG; Seroogy, JJ; Wolff, AA | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M | 1 |
| Bertucci, D; Douglass, EC; Fleming, GF; Ratain, MJ; Sawyer, MB; Schilsky, RL; Shulman, K; Smith, RP; Vogelzang, NJ | 1 |
| Igarashi, T; Imamura, F; Nakamura, S; Ueno, K; Yamamoto, S; Yoshimura, M | 1 |
| Clausen, NT; Hansen, PB; Hasselbalch, HC; Jensen, BA; Mourits-Andersen, T; Nielsen, OJ; Penninga, E | 1 |
| Bernasconi, S; Bizzoni, L; Dragoni, F; Latagliata, R; Mandelli, F; Mazzucconi, MG; Redi, R; Santoro, C | 1 |
| Aparicio, J; Balcells, M; Bosch, C; Busquier, I; Campos, JM; Galán, A; Garcerá, S; Llorca, C; López-Tendero, P; Maestu, I; Vicent, JM | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Cervantes, F | 1 |
| Norman, P | 1 |
| Clarke, S; Cunningham, D; Facchini, T; González Barón, M; James, R; Maroun, J; Maughan, TS; Schulz, J; Vincent, M; Zalcberg, J | 1 |
| Buchholz, E; Kloeppel, R; Kreisel, C; Manegold, C; Smith, M | 1 |
3 review(s) available for quinazolines and Anemia
| Article | Year |
|---|---|
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induced Liver Injury; Colorectal Neoplasms; Fluorouracil; Humans; Leucovorin; Mucositis; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Stomatitis; Thiophenes; Vomiting | 2014 |
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000.
Topics: Aged; Anemia; Aneuploidy; Angiogenesis Inhibitors; Bone Marrow Transplantation; Case Management; Combined Modality Therapy; Female; Hemoglobins; Humans; Hydroxyurea; Karyotyping; Male; Middle Aged; Palliative Care; Primary Myelofibrosis; Prognosis; Quinazolines; Risk; Severity of Illness Index; Splenectomy; Survival Analysis; Thalidomide | 2001 |
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Diarrhea; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pain; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Thiophenes; Vomiting | 2002 |
11 trial(s) available for quinazolines and Anemia
| Article | Year |
|---|---|
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Topics: Ado-Trastuzumab Emtansine; Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Lapatinib; Male; Maytansine; Middle Aged; Quinazolines; Receptor, ErbB-2; Response Evaluation Criteria in Solid Tumors; Retreatment; Survival Rate; Taxoids; Thrombocytopenia; Trastuzumab; Vomiting; Young Adult | 2017 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Topics: Adult; Alanine Transaminase; Anemia; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Breast Neoplasms; Diarrhea; Drug Administration Schedule; Female; Humans; Kinesins; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Quinazolines; Thrombocytopenia | 2003 |
Severe myelotoxicity in a combination of gefitinib and vinorelbine.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Quinazolines; Thrombocytopenia; Vinblastine; Vinorelbine | 2004 |
Anagrelide treatment in 52 patients with chronic myeloproliferative diseases.
Topics: Adult; Aged; Anemia; Chronic Disease; Female; Hemorrhage; Humans; Male; Middle Aged; Myeloproliferative Disorders; Platelet Aggregation Inhibitors; Quinazolines; Retrospective Studies; Thrombocytosis; Thromboembolism; Treatment Outcome | 2004 |
First-line treatment with irinotecan and raltitrexed in metastatic colorectal cancer. Mature results of a multicenter phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Colorectal Neoplasms; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Incidence; Irinotecan; Male; Middle Aged; Neutropenia; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Vomiting | 2005 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Phase I dose-escalating study of raltitrexed ('Tomudex') and cisplatin in metastatic non-small cell lung cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Quinazolines; Thiophenes; Thrombocytopenia | 2002 |
8 other study(ies) available for quinazolines and Anemia
| Article | Year |
|---|---|
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the "Ph1-negative Myeloproliferative Neoplasms Latium Group".
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anemia; Disease Management; Disease Susceptibility; Drug Substitution; Female; Follow-Up Studies; Health Care Surveys; Humans; Italy; Male; Middle Aged; Pregnancy; Pregnancy Complications, Hematologic; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Thrombocythemia, Essential; Thrombosis; Treatment Outcome; Young Adult | 2020 |
Stimulation of Eryptosis by Afatinib.
Topics: Afatinib; Anemia; Calcium Signaling; Eryptosis; Erythrocyte Membrane; Humans; Phospholipids; Quinazolines | 2018 |
Discovery of DS42450411 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4-aminopyrimidine derivatives.
Topics: Administration, Oral; Aminopyridines; Anemia; Animals; Binding Sites; Cell Line, Tumor; Drug Design; Hepcidins; Humans; Inflammation; Interleukin-6; Iron; Male; Mice, Inbred C57BL; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2018 |
Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Calreticulin; Child; Female; Follow-Up Studies; Gene Expression; Humans; Janus Kinase 2; Male; Middle Aged; Mutation; Platelet Aggregation Inhibitors; Primary Myelofibrosis; Quinazolines; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incidence; Middle Aged; Quinazolines; Risk; Thrombocythemia, Essential; Thrombophilia; Thrombosis | 2003 |
A long-term study of young patients with essential thrombocythemia treated with anagrelide.
Topics: Adult; Anemia; Female; Hemoglobins; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quinazolines; Stomach Diseases; Tachycardia; Thrombocythemia, Essential; Time Factors | 2004 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |